AC 7700

Known as: AVE8062, Combretastatin A4 Analogue AVE8062, AC7700 
 

Topic mentions per year

Topic mentions per year

1999-2016
02419992016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
OBJECTIVES To evaluate the early tumor vasculature disrupting effects of the AVE8062 molecule and the feasibility of dynamic… (More)
Is this relevant?
2007
2007
The purpose of this study was to examine the therapeutic efficacy and underlying mechanisms of action of a vascular-disrupting… (More)
Is this relevant?
2003
2003
The in vivo combination effect of AC-7700, a novel combretastatin A-4 derivative, and cisplatin (CDDP) was examined. The… (More)
Is this relevant?
2003
2003
We previously reported that a novel combretastatin A-4 derivative, AC7700, has remarkable antitumour effects because of an… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
2003
2003
A novel combretastatin A-4 derivative, AC7700, which is now in Phase I clinical trials under a new code, AVE8062, has shown… (More)
Is this relevant?
2002
2002
Background. Unlike the many chemotherapeutic agents that do not effectively stop blood flow or induce necrosis in hepatocellular… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2002
2002
In a previous study, we used subcutaneous LY80 tumours (a subline of Yoshida sarcoma), Sato lung carcinoma, and… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2001
2001
BACKGROUND Using several transplanted tumors in rats and mice, we have recently shown that the acute extensive necrosis of tumor… (More)
Is this relevant?
1999
1999
AC-7700, a novel combretastatin A-4 derivative, suppresses the growth of solid tumors by inhibiting tumor perfusion. We evaluated… (More)
Is this relevant?
1999
1999
The relation between tumor tissue blood flow (tBF) reduction and antitumor effects was investigated. Changes in tBF of normal… (More)
Is this relevant?